Accuray reported Q3 fiscal 2026 results on May 6 that landed squarely on the wrong side of expectations — and the company went further, pulling its full-year guidance entirely.
The headline numbers told the story bluntly. Q3 EPS came in at -$0.09 against a -$0.04 estimate. Revenue of $104.8 million missed the $111.9 million consensus by more than 6%. Management cited geopolitical uncertainty in the Middle East as the proximate cause, pointing to delayed installations that hit both shipments and service revenue. Guidance withdrawal on a miss of that scale signals that visibility has deteriorated, not merely slipped.
The bear case — that US-China tariffs, geopolitical tensions, and poor product mix would depress margins — was already circulating before the print. The result validated those concerns. Revenue has now disappointed twice in recent memory. After February's earnings, the stock fell 20% the next session and lost 32% over the following five days. The April 29 print offered a partial reprieve — shares bounced 7.8% the next day — but even that read was clouded: Friday's Q3 miss and guidance pull erase much of the narrative recovery that bounce implied.
The positioning picture reflects genuine short pressure for a stock of this size. Short interest runs at 6.6% of the free float — elevated territory for a small-cap medical device name — and has edged 5% higher over the past month, even as it drifted slightly lower week-on-week. The ORTEX short score of 54.8, after peaking near 58 on April 30, remains firmly in the cautious half of its range. Availability in the lending market is not extreme — borrow costs have actually eased this week, dropping to 0.65% from 0.88% a week ago — suggesting no mechanical squeeze pressure. This is bearish conviction, not forced covering.
Options traders have not crowded into puts. The put/call ratio of 0.053 is barely below its 20-day average of 0.056, and its 52-week low is 0.014 — meaning the ratio is running near the call-dominated end of its annual range. With a stock trading near $0.46, options activity is thin, but the direction of that thin market is not defensive. That divergence — shorts holding positions while options lean call-side — makes the post-earnings setup harder to read cleanly.
The institutional register adds a notable data point. TCW Group entered the share register recently with a 13% stake, last reported April 17, representing a fresh full position of 15.5 million shares. Independent Director Steven Mayer accumulated 250,000 shares across three open-market buys in mid-to-late February at prices between $0.53 and $0.56 — above where the stock trades today — suggesting board-level conviction that has not yet been rewarded. The net insider position is positive over the trailing 90 days, though the dollar amounts are small given the price level.
The analyst data is stale. The most recent price target on file — BTIG's $2.00, set in February 2026 — is already disconnected from current trading. With the stock near $0.46 and guidance now withdrawn, that target carries little weight. What the withdrawn guidance means for consensus is the more pressing question, and it will take updated analyst notes to reset the framework. For now, the key watch point is whether the Street downgrades its rating alongside the target, or whether it holds Buy ratings on a name that has lost its own forward visibility.
See the live data behind this article on ORTEX.
Open ARAY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
